Translational Research
Volume 156, Issue 4 , Pages 207-215 , October 2010

Lactoferrin modulation of mycobacterial cord factor trehalose 6-6'-dimycolate induced granulomatous response

  • Kerry J. Welsh

      Affiliations

    • Medical School, Department of Pathology and Laboratory Medicine, University of Texas-Houston, Houston, Tex
    • Graduate School of Biomedical Sciences, University of Texas-Houston, Houston, Tex
    • Kerry J. Welsh, MPH is medical student in her fifth year of a dual MD/PhD degree program offered by University of Texas-Houston. Her article is based on a presentation given at the Combined Annual Meeting of the Central Society for Clinical Research and Midwestern Section American Federation for Medical Research held in Chicago, lll, April 2010.
    • ,
  • Shen-An Hwang

      Affiliations

    • Medical School, Department of Pathology and Laboratory Medicine, University of Texas-Houston, Houston, Tex
    • ,
  • Robert L. Hunter

      Affiliations

    • Medical School, Department of Pathology and Laboratory Medicine, University of Texas-Houston, Houston, Tex
    • ,
  • Marian L. Kruzel

      Affiliations

    • Department of Integrative Biology and Pharmacology, University of Texas-Houston, Houston, Tex
    • ,
  • Jeffrey K. Actor

      Affiliations

    • Medical School, Department of Pathology and Laboratory Medicine, University of Texas-Houston, Houston, Tex
    • Corresponding Author InformationReprint requests: Jeffrey K. Actor, PhD, Department of Pathology and Laboratory Medicine, MSB 2.214, University of Texas-Houston Medical School, 6431 Fannin, Houston, Tex 77030

Received 29 April 2010 ,Revised 3 June 2010 ,Accepted 7 June 2010.

References 

  1. WHO. WHO report 2009. Global tuberculosis control. Epidemiology, strategy, financing. Geneva, Switzerland: World Health Organization; 2009;
  2. Gillespie SH, Kennedy N. Fluoroquinolones: a new treatment for tuberculosis?. Int J Tuberc Lung Dis. 1998;2:265–271
  3. Russell DG, Cardona PJ, Kim MJ, Allain S, Altare F. Foamy macrophages and the progression of the human tuberculosis granuloma. Nat Immunol. 2009;10:943–948
  4. Churchyard GJ, Kaplan G, Fallows D, Wallis RS, Onyebujoh P, Rook GA. Advances in immunotherapy for tuberculosis treatment. Clin Chest Med. 2009;30:769–782
  5. Wayne LG, Sohaskey CD. Nonreplicating persistence of mycobacterium tuberculosis. Annu Rev Microbiol. 2001;55:139–163
  6. Hunter RL, Armitige L, Jagannath C, Actor JK. TB research at UT-Houston—a review of cord factor: new approaches to drugs, vaccines and the pathogenesis of tuberculosis. Tuberculosis. 2009;89:S18–S25
  7. Actor JK, Hwang SA, Kruzel ML. Lactoferrin as a natural immune modulator. Curr Pharm Des. 2009;15:1956–1973
  8. Birgens HS. The interaction of lactoferrin with human monocytes. Dan Med Bull. 1991;38:244–252
  9. Hammarstrom ML, Mincheva-Nilsson L, Hammarstrom S. Functional lactoferrin receptors on activated human lymphocytes. Adv Exp Med Biol. 1995;371A:47–53
  10. Iyer S, Yip TT, Hutchens TW, Lonnerdal B. Lactoferrin-receptor interaction. Effect of surface exposed histidine residues. Adv Exp Med Biol. 1994;357:245–252
  11. Actor JK, Hwang SA, Olsen M, Zimecki M, Hunter RL, Kruzel ML. Lactoferrin immunomodulation of DTH response in mice. Int Immunopharmacol. 2002;2:475–486
  12. Damiens E, Mazurier J, el Yazidi I, et al. Effects of lactoferrin on NK cell cytotoxicity again haematopoietic and epithelial tumour cells. Biochim Biophys Acta. 1998;1402:277–287
  13. Legrand D, Elass E, Carpentier M, Mazurier J. Lactoferrin: a modulator of immune and inflammatory responses. Cell Mol Life Sci. 2005;62:2549–2559
  14. Shau H, Kim A, Golub SH. Modulation of natural killer and lymphokine-activated killer cell cytotoxicity by lactoferrin. J Leukoc Biol. 1992;51:343–349
  15. Zimecki M, Mazurier J, Spik G, Kapp JA. Human lactoferrin induces phenotypic and functional changes in murine splenic B cells. Immunology. 1995;86:122–127
  16. Sorimachi K, Akimoto K, Hattori Y, Ieiri T, Niwa A. Activation of macrophages by lactoferrin: secretion of TNF-alpha, IL-8 and NO. Biochem Mol Biol Int. 1997;43:79–87
  17. Wilk KM, Hwang SA, Actor JK. Lactoferrin modulation of antigen-presenting-cell response to BCG infection. Postepy Hig Med Dosw. 2007;61:277–282
  18. Kruzel ML, Actor JK, Boldogh I, Zimecki M. Lactoferrin in health and disease. Postepy Hig Med Dosw. 2007;61:261–267
  19. Hwang SA, Wilk KM, Bangale YA, Kruzel ML, Actor JK. Lactoferrin modulation of IL-12 and IL-10 response from activated murine leukocytes. Med Microbiol Immunol. 2007;196:171–180
  20. Kruzel ML, Harari Y, Chen CY, Castro GA. Lactoferrin protects gut mucosal integrity during endotoxemia induced by lipopolysaccharide in mice. Inflammation. 2000;24:33–44
  21. Hwang SA, Wilk K, Kruzel ML, Actor JK. A novel recombinant human lactoferrin augments the BCG vaccine and protects alveolar integrity upon infection with Mycobacterium tuberculosis in mice. Vaccine. 2009;27:3026–3034
  22. Hunter RL, Olsen MR, Jagannath C, Actor JK. Multiple roles of cord factor in the pathogenesis of primary, secondary, and cavitary tuberculosis, including a revised description of the pathology of secondary disease. Ann Clin Lab Sci. 2006;36:371–386
  23. Hunter RL, Olsen M, Jagannath C, Actor JK. Trehalose 6,6'-dimycolate and lipid in the pathogenesis of caseating granulomas of tuberculosis in mice. Am J Pathol. 2006;168:1249–1261
  24. Abbott AN, Guidry TV, Welsh KJ, et al. 11beta-hydroxysteroid dehydrogenases are regulated during the pulmonary granulomatous response to the mycobacterial glycolipid trehalose-6,6'-dimycolate. Neuroimmunomodulation. 2009;16:147–154
  25. Welsh KJ, Abbott AN, Hwang SA, et al. A role for tumour necrosis factor-alpha, complement C5 and interleukin-6 in the initiation and development of the mycobacterial cord factor trehalose 6,6'-dimycolate induced granulomatous response. Microbiology. 2008;154:1813–1824
  26. Bekierkunst A, Yarkoni E. Granulomatous hypersensitivity to trehalose-6,6'-dimycolate (cord factor) in mice infected with BCG. Infect Immun. 1973;7:631–638
  27. Perez RL, Roman J, Roser S, et al. Cytokine message and protein expression during lung granuloma formation and resolution induced by the mycobacterial cord factor trehalose-6,6'-dimycolate. J Interferon Cytokine Res. 2000;20:795–804
  28. Yamagami H, Matsumoto T, Fujiwara N, et al. Trehalose 6,6'-dimycolate (cord factor) of Mycobacterium tuberculosis induces foreign-body- and hypersensitivity-type granulomas in mice. Infect Immun. 2001;69:810–815
  29. Guidry TV, Hunter RL, Actor JK. Mycobacterial glycolipid trehalose 6,6'-dimycolate-induced hypersensitive granulomas: contribution of CD4+ lymphocytes. Microbiology. 2007;153:3360–3369
  30. Hwang SA, Actor JK. Lactoferrin modulation of BCG-infected dendritic cell functions. Int Immunol. 2009;21:1185–1197
  31. Hwang SA, Kruzel ML, Actor JK. Influence of bovine lactoferrin on expression of presentation molecules on BCG-infected bone marrow derived macrophages. Biochimie. 2009;91:76–85
  32. Kan-Sutton C, Jagannath C, Hunter RL. Trehalose 6,6'-dimycolate on the surface of Mycobacterium tuberculosis modulates surface marker expression for antigen presentation and costimulation in murine macrophages. Microbes Infect. 2009;11:40–48
  33. Indrigo J, Hunter RL, Actor JK. Influence of trehalose 6,6'-dimycolate (TDM) during mycobacterial infection of bone marrow macrophages. Microbiology. 2002;148:1991–1998
  34. Algood HM, Lin PL, Flynn JL. Tumor necrosis factor and chemokine interactions in the formation and maintenance of granulomas in tuberculosis. Clin Infect Dis. 2005;41:S189–S193
  35. Kaneko H, Yamada H, Mizuno S, et al. Role of tumor necrosis factor-alpha in Mycobacterium-induced granuloma formation in tumor necrosis factor-alpha-deficient mice. Lab Invest. 1999;79:379–386
  36. Kindler V, Sappino AP, Grau GE, Piguet PF, Vassalli P. The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection. Cell. 1989;56:731–740
  37. Roy E, Lowrie DB, Jolles SR. Current strategies in TB immunotherapy. Curr Mol Med. 2007;7:373–386
  38. Paige C, Bishai WR. Penitentiary or penthouse condo: the tuberculous granuloma from the microbe's point of view. Cell Microbiol. 2010;12:301–309
  39. Wallis RS, Kyambadde P, Johnson JL, et al. A study of the safety, immunology, virology, and microbiology of adjunctive etanercept in HIV-1-associated tuberculosis. AIDS. 2004;18:257–264
  40. Mayanja-Kizza H, Jones-Lopez E, Okwera A, et al. Immunoadjuvant prednisolone therapy for HIV-associated tuberculosis: a phase 2 clinical trial in Uganda. J Infect Dis. 2005;191:856–865
  41. Manzoni P, Rinaldi M, Cattani S, et al. Bovine lactoferrin supplementation for prevention of late-onset sepsis in very low-birth-weight neonates: a randomized trial. JAMA. 2009;302:1421–1428
  42. Tamano S, Sekine K, Takase M, Yamauchi K, Iigo M, Tsuda H. Lack of chronic oral toxicity of chemopreventive bovine lactoferrin in F344/DuCrj rats. Asian Pac J Cancer Prev. 2008;9:313–316
  43. Ueno H, Sato T, Yamamoto S, et al. Randomized, double-blind, placebo-controlled trial of bovine lactoferrin in patients with chronic hepatitis C. Cancer Sci. 2006;97:1105–1110
  44. Manzoni P, Decembrino L, Stolfi I, et al. Lactoferrin and prevention of late-onset sepsis in the preterm neonate in the NICU. Early Hum Dev. 2010;Suppl 1:59–61.
  45. Li MO, Flavell RA. Contextual regulation of inflammation: a duet by transforming growth factor-beta and interleukin-10. Immunity. 2008;28:468–476
  46. Co DO, Hogan LH, Kim SI, Sandor M. Mycobacterial granulomas: keys to a long-lasting host-pathogen relationship. Clin Immunol. 2004;113:130–136
  47. Jouanguy E, Altare F, Lamhamedi S, et al. Interferon-gamma-receptor deficiency in an infant with fatal bacille Calmette-Guerin infection. N Engl J Med. 1996;335:1956–1961
  48. Chan J, Flynn J. The immunological aspects of latency in tuberculosis. Clin Immunol. 2004;110:2–12
  49. Gonzalez-Juarrero M, Hattle JM, Izzo A, et al. Disruption of granulocyte macrophage-colony stimulating factor production in the lungs severely affects the ability of mice to control Mycobacterium tuberculosis infection. J Leukoc Biol. 2005;77:914–922
  50. Togawa J, Nagase H, Tanaka K, et al. Lactoferrin reduces colitis in rats via modulation of the immune system and correction of cytokine imbalance. Am J Physiol Gastrointest Liver Physiol. 2002;283:G187–G195
  51. Kruzel ML, Harari Y, Chen CY, Castro GA. The gut. A key metabolic organ protected by lactoferrin during experimental systemic inflammation in mice. Adv Exp Med Biol. 1998;443:167–173
  52. Kocieba M, Zimecki M, Kruzel M, Actor J. The adjuvant activity of lactoferrin in the generation of DTH to ovalbumin can be inhibited by bovine serum albumin bearing alpha-D-mannopyranosyl residues. Cell Mol Biol Lett. 2002;7:1131–1136
  53. Zimecki M, Kruzel ML. Systemic or local co-administration of lactoferrin with sensitizing dose of antigen enhances delayed type hypersensitivity in mice. Immunol Lett. 2000;74:183–188
  54. Ishikawa E, Ishikawa T, Morita YS, et al. Direct recognition of the mycobacterial glycolipid, trehalose dimycolate, by C-type lectin Mincle. J Exp Med. 2009;206:2879–2888

 Supported by NIH-NIAID Grant R42-AI051050-04.

PII: S1931-5244(10)00116-7

doi: 10.1016/j.trsl.2010.06.001

Translational Research
Volume 156, Issue 4 , Pages 207-215 , October 2010

Article Tools

* Image Usage & Resolution